News
Atara Biotherapeutics Inc (NASDAQ: ATRA) announced an update to its existing collaboration agreement with Pierre Fabre for the commercialization of tabelecleucel (tab-cel) for Epstein-Barr virus ...
Under the agreement, Scorpion will lead clinical development of STX-721 and Pierre Fabre will lead clinical development of STX-241. Scorpion will retain commercialization rights to STX-721 and STX-241 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback